Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

New Product Planning Spend Up to Half their Time on BD

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
A new survey of drug manufacturers found that new product planning teams dedicate upwards of 50% of their time on business development activities.

New product planning teams have taken on responsibilities beyond acting as a developing product’s commercial voice. The recent study published by Cutting Edge Information shows that among surveyed companies, 100% of new product planning teams are involved in business development. These activities range from generating commercial assessments to contributing to the go/no go decisions made by the business development function.

Company needs dictate the extent of new product planning involvement in these business development activities. Often, companies shift new product planning responsibilities and resources to reflect the current business quarter and the developing product’s timeline. While all surveyed companies leverage their NPP teams to provide initial input on upcoming business development deals, an estimated one third also use their teams either to identify potential opportunities early or to participate during the later decision making stages.

Companies benefit from incorporating the new product planning function into business development because new product planning teams are able to evaluate the commercial viability of a deal early and objectively. “New product planning teams use preliminary scientific evaluations and commercial profiles to provide business development teams with an unbiased perspective,” said David Richardson, research team manager at Cutting Edge Information. Consequently, new product planning support helps companies allocate their resources wisely and pursue advantageous pharma partnerships.

“Pharmaceutical New Product Planning: Building the Framework for Brand Commercialization,” ( features detailed data on new product planning’s early commercialization efforts including team structure and reporting lines, budget and spending, staffing—encompassing staff education levels, background and compensation metrics—and business development efforts. This study is designed to help pharmaceutical companies:

•    Increase new product planning resources to support growing brand responsibilities as developing products move closer to launch.
•    Communicate and work with clinical teams to insert commercially focused data collection into clinical trials.
•    Facilitate easy transition of brand responsibility between teams by leveraging new product planning team members’ expertise.
•    Leverage new product planning teams’ scientific and commercial expertise and unbiased perspectives to support business development groups.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Patient Enrollment is a Critical Cost Driver in Phase 1 Clinical Trials
Cutting Edge Information’s recent study of oncology trials revealed a strong correlation between number of patients and trial cost.
Wednesday, June 19, 2013
New Product Launches Double Medical Affairs Spending
Cutting Edge Information’s new study finds that some companies increase medical affairs budgets by 100% preceding a product launch.
Tuesday, April 16, 2013
Increase in Pharmaceutical Companies Outsourcing Regulatory Affairs Budgets
A recent study by Cutting Edge Information shows outsourcing becoming more common for regulatory affairs tasks.
Thursday, January 10, 2013
Increase in Pharmaceutical Companies Outsourcing Regulatory Affairs Budgets
A recent study by Cutting Edge Information shows outsourcing becoming more common for regulatory affairs tasks.
Thursday, January 10, 2013
Increase in Pharmaceutical Companies Outsourcing Regulatory Affairs Budgets
A recent study by Cutting Edge Information shows outsourcing becoming more common for regulatory affairs tasks.
Thursday, January 10, 2013
Central and Eastern Europe Building Clinical Trial Success
Development teams benefit from tougher investigator standards and active patient populations, finds Cutting Edge Information.
Monday, February 14, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos